Get started
Work

First Results of a Head‐to‐head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia

Year: 2021
Type: article
DOI: 10.1002/hon.33_2879
Authors: P. Hillmen, J. C. Byrd, P. Ghia, A. P. Kater, A. Chanan‐Khan, R. R. Furman, S. O'Brien, M. N. Yenerel, A. Illes, N. Kay, J. A. Garcia‐Marco, A. Mato, J. Pinilla‐Ibarz, J. F. Seymour, S. Lepretre, S. Stilgenbauer, T. Robak, P. Patel, K. Higgins, S. Sohoni, W. Jurczak
Institutions: St James's University Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Hovon, Amsterdam University Medical Centers, Mayo Clinic, Mayo Clinic in Florida, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill Cornell Medical Center, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, Istanbul University, University of Debrecen, Hospital Universitario Puerta de Hierro Majadahonda, University of Pennsylvania, Moffitt Cancer Center, The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Centre Henri Becquerel, Université de Rouen Normandie, Universität Ulm, Medical University of Lodz, AstraZeneca (United States), The Maria Sklodowska-Curie National Research Institute of Oncology
Language: English
Subfield: Genetics
Field: Medicine
Open Access status: closed
OpenAlex ID: W3177065852
FWCI: 0.882
Cites:
Cited by: 8
Related to: 10